Cash flow is strong; income statement is moderate; balance sheet is weak.
Next earnings: 2026-10-28 (BMO), EPS Forecast: $1.21
Upgraded from Sell to Hold in the Mar 2025 quarter: 45.3 → 48.1 (+2.8). This quarter: -0.4.
Change vs previous quarter.
ge healthcare (nyse: ge) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. while we encourage and welcome comments to our linkedin page, these posts from members of the public do not necessarily represent ge healthcare views, and we do not confirm their accuracy or endorse them. ge healthcare is part of highly regulated medical device and pharmaceutical industry. posts and conversations may be removed as a result, but may be forwarded to other people within ge healthcare for follow-up as appropriate. as part of our commitment to you and to the rest of the linkedin members, we will do our best to ensure that the content on the page remains positive. however, since we cannot monitor every post or conversation feed, we realize that the occasional objectionable posts will pop up just from time to time. therefore, the company reserves the right to remove any postings at i